640 related articles for article (PubMed ID: 26976826)
41. Targeting Resident Memory T Cells for Cancer Immunotherapy.
Blanc C; Hans S; Tran T; Granier C; Saldman A; Anson M; Oudard S; Tartour E
Front Immunol; 2018; 9():1722. PubMed ID: 30100906
[TBL] [Abstract][Full Text] [Related]
42. Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.
Klebanoff CA; Scott CD; Leonardi AJ; Yamamoto TN; Cruz AC; Ouyang C; Ramaswamy M; Roychoudhuri R; Ji Y; Eil RL; Sukumar M; Crompton JG; Palmer DC; Borman ZA; Clever D; Thomas SK; Patel S; Yu Z; Muranski P; Liu H; Wang E; Marincola FM; Gros A; Gattinoni L; Rosenberg SA; Siegel RM; Restifo NP
J Clin Invest; 2016 Jan; 126(1):318-34. PubMed ID: 26657860
[TBL] [Abstract][Full Text] [Related]
43. Form and function for T cells in health and disease.
Farber DL
Nat Rev Immunol; 2020 Feb; 20(2):83-84. PubMed ID: 31889162
[No Abstract] [Full Text] [Related]
44. Adoptive immunotherapy for cancer: building on success.
Gattinoni L; Powell DJ; Rosenberg SA; Restifo NP
Nat Rev Immunol; 2006 May; 6(5):383-93. PubMed ID: 16622476
[TBL] [Abstract][Full Text] [Related]
45. Adoptive immunotherapy for cancer: harnessing the T cell response.
Restifo NP; Dudley ME; Rosenberg SA
Nat Rev Immunol; 2012 Mar; 12(4):269-81. PubMed ID: 22437939
[TBL] [Abstract][Full Text] [Related]
46. The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer.
Beumer-Chuwonpad A; Taggenbrock RLRE; Ngo TA; van Gisbergen KPJM
Cells; 2021 Aug; 10(9):. PubMed ID: 34571883
[TBL] [Abstract][Full Text] [Related]
47. Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours?
Perret R; Ronchese F
Tissue Antigens; 2008 Sep; 72(3):187-94. PubMed ID: 18627571
[TBL] [Abstract][Full Text] [Related]
48. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
[TBL] [Abstract][Full Text] [Related]
49. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
[TBL] [Abstract][Full Text] [Related]
50. Rise of iPSCs as a cell source for adoptive immunotherapy.
Minagawa A; Kaneko S
Hum Cell; 2014 Apr; 27(2):47-50. PubMed ID: 24510519
[TBL] [Abstract][Full Text] [Related]
51. T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up!
Porter DL; June CH
Bone Marrow Transplant; 2005 May; 35(10):935-42. PubMed ID: 15806121
[TBL] [Abstract][Full Text] [Related]
52. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells.
Graef P; Buchholz VR; Stemberger C; Flossdorf M; Henkel L; Schiemann M; Drexler I; Höfer T; Riddell SR; Busch DH
Immunity; 2014 Jul; 41(1):116-26. PubMed ID: 25035956
[TBL] [Abstract][Full Text] [Related]
53. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells.
Plautz GE; Touhalisky JE; Shu S
Cell Immunol; 1997 Jun; 178(2):101-7. PubMed ID: 9225000
[TBL] [Abstract][Full Text] [Related]
54. Analysis of the adoptive transfer of delayed hypersensitivity and T cell repertoire in severe combined immunodeficiency mice reconstituted with human lymphocytes.
Mancia L; Mariani F; Mattei M; Montesano C; Placido R; Colizzi V; Salerno A; Bellavia A
Folia Biol (Praha); 1994; 40(6):411-30. PubMed ID: 7589700
[TBL] [Abstract][Full Text] [Related]
55. Tissue-resident memory T cells: local specialists in immune defence.
Mueller SN; Mackay LK
Nat Rev Immunol; 2016 Feb; 16(2):79-89. PubMed ID: 26688350
[TBL] [Abstract][Full Text] [Related]
56. Genetically engineered T cells as adoptive immunotherapy of cancer.
Ma Q; Gonzalo-Daganzo RM; Junghans RP
Cancer Chemother Biol Response Modif; 2002; 20():315-41. PubMed ID: 12703212
[No Abstract] [Full Text] [Related]
57. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation.
Feuchtinger T; Richard C; Joachim S; Scheible MH; Schumm M; Hamprecht K; Martin D; Jahn G; Handgretinger R; Lang P
J Immunother; 2008; 31(2):199-206. PubMed ID: 18481389
[TBL] [Abstract][Full Text] [Related]
58. [Cancer immunotherapy and immunological memory].
Murata K; Tsukahara T; Torigoe T
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(1):18-22. PubMed ID: 27181230
[TBL] [Abstract][Full Text] [Related]
59. Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues.
Ebert LM; Schaerli P; Moser B
Mol Immunol; 2005 May; 42(7):799-809. PubMed ID: 15829268
[TBL] [Abstract][Full Text] [Related]
60. CMV-Specific CD8 T Cell Differentiation and Localization: Implications for Adoptive Therapies.
Smith CJ; Quinn M; Snyder CM
Front Immunol; 2016; 7():352. PubMed ID: 27695453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
